246 related articles for article (PubMed ID: 37899132)
1. Multiplex imaging in immuno-oncology.
Zhao C; Germain RN
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899132
[TBL] [Abstract][Full Text] [Related]
2. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
3. New Immuno-oncology Targets and Resistance Mechanisms.
Tokaz MC; Baik CS; Houghton AM; Tseng D
Curr Treat Options Oncol; 2022 Sep; 23(9):1201-1218. PubMed ID: 35980521
[TBL] [Abstract][Full Text] [Related]
4. Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology.
Arulraj T; Wang H; Ippolito A; Zhang S; Fertig EJ; Popel AS
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38557676
[TBL] [Abstract][Full Text] [Related]
5. Immunodynamics of explanted human tumors for immuno-oncology.
Dubuisson A; Fahrner JE; Goubet AG; Terrisse S; Voisin N; Bayard C; Lofek S; Drubay D; Bredel D; Mouraud S; Susini S; Cogdill A; Rebuffet L; Ballot E; Jacquelot N; Thomas de Montpreville V; Casiraghi O; Radulescu C; Ferlicot S; Figueroa DJ; Yadavilli S; Waight JD; Ballas M; Hoos A; Condamine T; Parier B; Gaudillat C; Routy B; Ghiringhelli F; Derosa L; Breuskin I; Rouanne M; André F; Lebacle C; Baumert H; Wislez M; Fadel E; Cremer I; Albiges L; Geoerger B; Scoazec JY; Loriot Y; Kroemer G; Marabelle A; Bonvalet M; Zitvogel L
EMBO Mol Med; 2021 Jan; 13(1):e12850. PubMed ID: 33372722
[TBL] [Abstract][Full Text] [Related]
6. Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies.
Altun I; Demirlenk YM; Atar D; Cevik E; Gunduz S; Albadawi H; Oklu R
J Vasc Interv Radiol; 2024 Feb; 35(2):164-172. PubMed ID: 38272636
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived preclinical models to develop immunotherapies.
Seoane J
Mol Oncol; 2023 Jul; 17(7):1169-1172. PubMed ID: 37278114
[TBL] [Abstract][Full Text] [Related]
8. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of epigenetic therapeutics in immuno-oncology.
Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
[TBL] [Abstract][Full Text] [Related]
10. Historical perspective and future directions: computational science in immuno-oncology.
Ricker CA; Meli K; Van Allen EM
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191244
[TBL] [Abstract][Full Text] [Related]
11. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
Chuntova P; Chow F; Watchmaker PB; Galvez M; Heimberger AB; Newell EW; Diaz A; DePinho RA; Li MO; Wherry EJ; Mitchell D; Terabe M; Wainwright DA; Berzofsky JA; Herold-Mende C; Heath JR; Lim M; Margolin KA; Chiocca EA; Kasahara N; Ellingson BM; Brown CE; Chen Y; Fecci PE; Reardon DA; Dunn GP; Liau LM; Costello JF; Wick W; Cloughesy T; Timmer WC; Wen PY; Prins RM; Platten M; Okada H
Neuro Oncol; 2021 Mar; 23(3):356-375. PubMed ID: 33367885
[TBL] [Abstract][Full Text] [Related]
12. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
[TBL] [Abstract][Full Text] [Related]
13. CAF-immune cell crosstalk and its impact in immunotherapy.
Maia A; Schöllhorn A; Schuhmacher J; Gouttefangeas C
Semin Immunopathol; 2023 Mar; 45(2):203-214. PubMed ID: 36480035
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
[TBL] [Abstract][Full Text] [Related]
15. Multi-Omics Profiling of the Tumor Microenvironment.
Van Oekelen O; Laganà A
Adv Exp Med Biol; 2022; 1361():283-326. PubMed ID: 35230695
[TBL] [Abstract][Full Text] [Related]
16. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
Front Immunol; 2019; 10():924. PubMed ID: 31134058
[TBL] [Abstract][Full Text] [Related]
18. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].
Kaplon H; Dieu-Nosjean MC
Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099
[TBL] [Abstract][Full Text] [Related]
19. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy.
Lee JY; Kannan B; Lim BY; Li Z; Lim AH; Loh JW; Ko TK; Ng CC; Chan JY
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887186
[TBL] [Abstract][Full Text] [Related]
20. Organoids as an Enabler of Precision Immuno-Oncology.
Zhao J; Fong A; Seow SV; Toh HC
Cells; 2023 Apr; 12(8):. PubMed ID: 37190074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
